Rapid progress was recently made in the treatment of prostate cancer, especially metastatic castration-resistant prostate cancer.
At the NCCN 18th Annual Conference, Dr. Philip W. Kantoff reviewed the data supporting the use of abiraterone acetate, enzalutamide, cabazitaxel, sipuleucel-T, and radium-223 (pending approval), and offered recommendations for their sequential use in different settings. Dr. James L. Mohler described factors that dictate who should receive treatment, when they should receive it, and how to treat in the setting of prostate-specific antigen elevation. He explained how better treatment decisions will result from individualized estimation of threat-to-life posed by prostate cancer, chance of cure by treatment, and treatment risks.
Written by:
Kantoff PW, Mohler JL. Are you the author?
The Lank Center for Genitourinary Oncology and Solid Tumor Oncology at the Dana-Farber Cancer Institute/Brigham & Women's Hospital, Boston, Massachusetts; Urology at Roswell Park Cancer Institute, Buffalo, New York.
Reference: J Natl Compr Canc Netw. 2013 May 1;11(5 Suppl):653-7.
PubMed Abstract
PMID: 23704236
UroToday.com Prostate Cancer Section
